Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 5 of a 5-Part Series

Meet The Professor: Optimizing the Management...

Research To PracticeResearch To Practice

Up next

Cases from the Community: Integrating New Research Findings into Current Practice — Gynecologic Cancers

Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers. 

 . 46min 41sec
Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 5-Part Series

Featuring a discussion on the treatment of ovarian cancer with Dr Richard Penson, moderated by Dr Neil Love. 

 . 1h 2min

Recommended Episodes

Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
BackTable Urology

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

 . 56min 23sec
Wanda Cui on measuring ovarian toxicity
The Lancet Oncology in conversation with

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

Read the full article:
<a href='https://www.thelancet.com/journals/lanonc/article/PIIS1470-20 ...

  Show more

 . 10min 37sec
Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Breast Cancer Update

Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here. 

 . 21min 51sec
Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

 . 59min 51sec